Professional Documents
Culture Documents
(Download PDF) Advances in Clinical Chemistry Volume 79 Gregory S Makowski Eds Online Ebook All Chapter PDF
(Download PDF) Advances in Clinical Chemistry Volume 79 Gregory S Makowski Eds Online Ebook All Chapter PDF
https://textbookfull.com/product/advances-in-clinical-chemistry-
volume-73-gregory-s-makowski/
https://textbookfull.com/product/advances-in-clinical-chemistry-
volume-78-gregory-s-makowski-eds/
https://textbookfull.com/product/advances-in-clinical-chemistry-
volume-81-gregory-s-makowski-eds/
https://textbookfull.com/product/advances-in-clinical-chemistry-
volume-67-1st-edition-gregory-s-makowski/
Advances in Clinical Chemistry 1st Edition Gregory
Makowski
https://textbookfull.com/product/advances-in-clinical-
chemistry-1st-edition-gregory-makowski/
https://textbookfull.com/product/advances-in-clinical-
chemistry-62-1st-edition-gregory-s-makowski-eds/
https://textbookfull.com/product/advances-in-clinical-
chemistry-63-1st-edition-gregory-s-makowski-eds/
https://textbookfull.com/product/advances-in-clinical-
chemistry-64-1st-edition-gregory-s-makowski-eds/
https://textbookfull.com/product/advances-in-clinical-
chemistry-74-1st-edition-gregory-s-makowski-eds/
Academic Press is an imprint of Elsevier
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States
525 B Street, Suite 1800, San Diego, CA 92101-4495, United States
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom
125 London Wall, London, EC2Y 5AS, United Kingdom
No part of this publication may be reproduced or transmitted in any form or by any means,
electronic or mechanical, including photocopying, recording, or any information storage and
retrieval system, without permission in writing from the publisher. Details on how to seek
permission, further information about the Publisher’s permissions policies and our
arrangements with organizations such as the Copyright Clearance Center and the Copyright
Licensing Agency, can be found at our website: www.elsevier.com/permissions.
This book and the individual contributions contained in it are protected under copyright by
the Publisher (other than as may be noted herein).
Notices
Knowledge and best practice in this field are constantly changing. As new research and
experience broaden our understanding, changes in research methods, professional practices,
or medical treatment may become necessary.
Practitioners and researchers must always rely on their own experience and knowledge in
evaluating and using any information, methods, compounds, or experiments described
herein. In using such information or methods they should be mindful of their own safety and
the safety of others, including parties for whom they have a professional responsibility.
To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors,
assume any liability for any injury and/or damage to persons or property as a matter of
products liability, negligence or otherwise, or from any use or operation of any methods,
products, instructions, or ideas contained in the material herein.
ISBN: 978-0-12-812076-7
ISSN: 0065-2423
M. Doosti
Department of Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences,
Tehran, Islamic Republic of Iran
S. Emamgholipour
Department of Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences,
Tehran, Islamic Republic of Iran
D. French
University of California San Francisco, San Francisco, CA, United States
F. Garlan
Universite Sorbonne Paris Cite, INSERM UMR-S1147, CNRS SNC 5014, Centre
Universitaire des Saints-Pères, Equipe labelisee LIGUE Contre le Cancer, Paris, France
H. Lu
Universite Sorbonne Paris Cite, INSERM UMR-S1147, CNRS SNC 5014, Centre
Universitaire des Saints-Pères, Equipe labelisee LIGUE Contre le Cancer, Paris, France
M. Matic
Institute of Medical and Clinical Biochemistry; Faculty of Medicine, University in Belgrade,
Belgrade, Serbia
G. Perkins
Universite Sorbonne Paris Cite, INSERM UMR-S1147, CNRS SNC 5014, Centre
Universitaire des Saints-Pères, Equipe labelisee LIGUE Contre le Cancer; European Georges
Pompidou Hospital, AP-HP - Paris Descartes University, Paris, France
M. Pljesa-Ercegovac
Institute of Medical and Clinical Biochemistry; Faculty of Medicine, University in Belgrade,
Belgrade, Serbia
S. Radovanovic
Medical Center “Bezanijska Kosa”, Belgrade, Serbia
M. Raman
University of Calgary, Calgary, AB, Canada
A. Savic-Radojevic
Institute of Medical and Clinical Biochemistry; Faculty of Medicine, University in Belgrade,
Belgrade, Serbia
P. Shabani
Department of Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences,
Tehran, Islamic Republic of Iran
D. Simic
Faculty of Medicine, University in Belgrade; Clinic for Cardiovascular Diseases, Clinical
Centre of Serbia, Belgrade, Serbia
ix
x Contributors
T. Simic
Institute of Medical and Clinical Biochemistry; Faculty of Medicine, University in Belgrade,
Belgrade, Serbia
V. Taly
Universite Sorbonne Paris Cite, INSERM UMR-S1147, CNRS SNC 5014, Centre
Universitaire des Saints-Pères, Equipe labelisee LIGUE Contre le Cancer, Paris, France
R. Tamura
BioFrontiers Institute, University of Colorado Boulder, Boulder, CO, United States
H. Yin
BioFrontiers Institute, University of Colorado Boulder, Boulder, CO, United States
PREFACE
The second volume of the Advances in Clinical Chemistry series for 2017 is
presented.
In Chapter 1, the role of adipokines in nonalcoholic fatty liver disease is
explored. These unique molecules include the CTRP family that modulates
numerous pathways including glucose and fatty acid metabolism and inflam-
mation. CTRP appears linked to disease pathogenesis, and as such, this
pleiotropic molecule may thus be suitable as a biomarker. In Chapter 2,
extracellular vesicles are highlighted. These unique submicroscopic lipid
vesicles, released from various cell types, play significant roles in transport of
cell signaling molecules in physiologic as well as pathophysiologic states. In
Chapter 3, the use of droplet-based polymerase chain reaction in cancer diag-
nostics is reviewed. This novel technology allows for the detection and
quantification of rare nucleic acid sequences with sensitivity and precision
previously unachievable by conventional methods. In Chapter 4, potential bio-
markers of heart failure are presented. This disease remains a continuing health
problem with increased incidence and prevalence. Biomarkers presented in this
comprehensive review include those associated with myocardial stretch,
injury, matrix remodeling, inflammation, renal dysfunction, neurohumoral
activation, and oxidative stress. In Chapter 5, the increasing application of mass
spectrometry in clinical laboratory diagnostics is reviewed. As a laboratory-
developed test, this approach has shown continual evolution and challenges
the use of traditional immunoassay methodology. Technologic advances and
new clinical applications will be discussed. In Chapter 6, the role of the
clinical laboratory is highlighted in diagnosis of chronic diarrhea. Diagnosis
of this frequently encountered symptom is complicated by its diverse etiology
and considerable overlap among its various forms such as malabsorptive, secre-
tory, osmotic, inflammatory, and motility-related. The selection of an appro-
priate screening/confirmation strategy is fundamental to effective treatment.
I thank Volume 79 contributors and colleagues for their peer review.
I extend thanks to Shellie Bryant and Vignesh Tamil for expert editorial
support.
I hope the second volume for 2017 will be enjoyed. Comments and
feedback from the readership are always appreciated.
I would like to dedicate Volume 79 to my wife Melinda on the occasion
of our 20th anniversary. It’s been wonderful.
GREGORY S. MAKOWSKI
xi
CHAPTER ONE
Contents
1. Introduction 2
2. Adiponectin and the C1q Family 3
3. CTRP1 Characteristics 5
3.1 Structure 5
3.2 Posttranslational Modifications of CTRP1 7
3.3 CTRP1 Expression 7
3.4 Serum Levels of CTRP1 8
4. Regulation of CTRP1 8
5. CTRP1 and NAFLD 9
5.1 CTRP1 Functions 9
6. Critical Evaluation of CTRP1 15
6.1 Insulin Resistance 16
6.2 CTRP1 and Obesity 16
6.3 CTRP1 and Atherosclerosis 17
7. Conclusion 17
References 18
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease occurs in significant per-
centage of general population. NAFLD is closely associated with entire spectrum of
metabolic-related disorders including diabetes, obesity, and cardiovascular diseases.
Considering several similar pathways underpinning metabolic disorders, presence of
common molecular mediators contributing to pathomechanism of these disorders is
expected. Mounting evidence has demonstrated important role of adipokines in the
context of NAFLD. Adipokines produced by different tissues, mainly adipose, modulate
numerous pathways including glucose and fatty acid metabolism and inflammation.
CTRPs (C1q/TNF-related proteins) are a recently identified family of adipokines in which
adiponectin is the most well-known ones. CTRP1 is a member of this family which has cap-
tured attention in recent years. CTRP1 enhances glucose and fatty acid oxidation, improves
insulin sensitivity, attenuates plaque formation, and increases aldosterone production.
Hence, various roles in metabolic pathways can link CTRP1 to NAFLD pathogenesis.
1
These authors contributed equally to this work.
1. INTRODUCTION
Liver diseases encompass viral hepatitis, nonalcoholic fatty liver disease
(NAFLD), alcoholic fatty liver disease, autoimmune liver diseases, genetic
liver diseases, and liver cancer. NAFLD is the most common disease affect-
ing a large number of people worldwide.
NAFLD remains among the most common chronic liver disease world-
wide. Depending on the studied populations, the prevalence of NAFLD has
been reported as a range from 6% to 33%. The presence of fat accumulation
in at least 5% of hepatocytes based on liver biopsy is a well-known charac-
teristics of NAFLD [1–3]. NAFLD encompasses a spectrum of liver disease
varying from simple steatosis to nonalcoholic steatohepatitis (NASH), fibro-
sis, and cirrhosis, which may finally develop to hepatocellular carcinoma
[4,5]. Liver cirrhosis may observe in one-third of NASH patients; however,
abundant data show that fibrosis may develop both in NASH and NAFLD
[6]. There is ample evidence that NAFLD is closely linked to insulin resis-
tance, obesity, metabolic syndrome, and inflammation [7–10].
Dysregulated fatty acid influx to the liver, impaired fatty acid efflux, and
defective de novo lipogenesis in liver cause increase in the hepatic lipid stor-
age [8,11–13]. Accumulating evidence pointed out that adipocytokines and
cytokines are major mediators in this process [14–18]. It is generally accepted
that insulin resistance is one of the most important components of NAFLD
and most patients with NAFLD and subjects who develop NASH also suffer
from diabetes [19]. Although the exact mechanism of NAFLD has not been
completely understood, a constellation of impaired inflammatory pathways,
oxidative stress, lipotoxicity, and mitochondrial dysfunction are involved in
NAFLD pathomechanism.
Insulin resistance is defined as the failure of peripheral tissues to respond
normally to insulin and contribute to related pathway of NAFLD pathogen-
esis [20,21].
Insulin is a multifunctional hormone that triggers cellular functions through
its interaction with the insulin receptor and consequently dimerization and
autophosphorylation of insulin receptor. There is evidence that alteration of
the phosphatidylinositol 3-kinase (PI3K)-protein kinase B (PKB/AKT) and
the mitogen-activated protein kinase (MAPK) pathways as two important
pathways which act downstream of insulin receptor can cause insulin resistance
[22,23]. Among different mediators contributing to insulin resistance, free
fatty acids (FFAs) have been considered the most important molecules in this
CTRP1 in Liver Disease 3
[41,42].There is ample evidence that this tissue is involved in the innate and
acquired immune responses. Specifically, adipose tissue secretes a wide range
of molecules such as pro- and antiinflammatory cytokines, adipokines, and
several molecules associated with the innate immune system (e.g., the
C1qTNF-related protein superfamily). Adipokines are a group of secretory
proteins initially released from adipocytes and play important roles in regu-
lating glucose and lipid metabolism, insulin signaling, and inflammatory
pathways directly and indirectly [43–46].
Among adipokines secreted from adipose tissue, adiponectin has
received a great deal of attention in experimental and clinical studies in
humans and in vitro investigations in transgenic and knockout (KO)
mice [47].
Adiponectin is an adipocyte-derived secretory protein that is composed
of 247 amino acids and has molecular weight of 30 kDa. This protein has
four distinct domains, and there are also five various configurations for
adiponectin, which binds three kinds of receptors [48,49]. Based on available
literature, adiponectin has been considered as reliable biomarker for several
disorders including diabetes, metabolic syndrome, fatty liver, and obesity
[50–52]. The well-known characteristic of adiponectin is the existence of
a globular C-terminal domain and a collagenous N-terminal domain. There
is evidence that posttranslational modification of the collagenous domain is
involved in trimers, hexamers, and higher-order complexes formation. It
was demonstrated that high-molecular-weight adiponectin is distinguish-
ably decreased in men in comparison with women and in subjects with obe-
sity and insulin resistance compared to lean and insulin-sensitive subjects
[53–55].
Structurally, adiponectin belongs to the C1q protein family which was
characterized based on having a C-terminal globular domain with sequence
homology to the immune complement protein C1q. The characterization
of adiponectin and its homotrimeric gC1 domain revealed that the structures
of TNF-ligand family proteins and the C1q complement family proteins
were diverged from a precursor recognition molecule of the innate immune
system. This evolutionary link suggests that these proteins have shared func-
tions too [49,56,57]. The C1q initiates activation of the classical pathway of
the complement pathway and plays an important role in cell adhesion, reg-
ulation of B lymphocytes, maintaining immune tolerance via removing apo-
ptotic cells and pathogens [57]. The most proportion of C1q ligands are
recognized by the globular (gC1q) domain that contains a versatile charge
pattern recognition region [57]. Specifically, the globular (gC1q) domain
CTRP1 in Liver Disease 5
3. CTRP1 CHARACTERISTICS
3.1 Structure
Wong et al. identified a highly conserved family of proteins homologous to
Acrp30/adiponectin by using GenBank EST and genomic databases with
the adiponectin cDNA sequence. As these proteins have a C1q-like globular
domain and a C-terminal complement factor C1q globular domain which
have 3D organization resembling TNF-α, they were nominated CTRP [64].
6 P. Shabani et al.
Fig. 1 Structure of the CTRP family members. (A) Domain structure of CTRP monomeric
protein which is composed of a signal peptide (S) at the N terminus, a variable region (V),
a collagen domain (Gly-X-Y), and a globular C1q/TNF domain at C terminus.
(B) Homotrimeric structure of CTRP. (C) Higher-order 3D structure of homotrimeric CTRP
proteins.
CTRP1 in Liver Disease 7
4. REGULATION OF CTRP1
Rosiglitazone is the thiazolidinedione compound that is well known
to improve insulin resistance through regulating adiponcetin gene expres-
sion. In addition, rosiglitazone is considered as transcription factor peroxi-
some proliferator-activated receptor g (PPARg) agonist [77,78]. Treatment
of mice with rosiglitazone daily for 3 weeks at a dose of 15 mg/kg aug-
mented the CTRP1 and adiponectin expression; however, it did not affect
the mRNA expression of CTRP2, CTRP3, CTRP5, CTRP7, and
CTRP10 [75].
There is also evidence that CTRP1 expression might be induced in
inflammatory conditions. Administration of lipopolysaccharide caused
increased CTRP1 gene expression in the epididymal adipose deposit in male
Sprague–Dawley (SD) rats. Despite that the level of CTRP1 gene expres-
sion was low in adipocytes, it was shown that CTRP1 gene expression was
highly detectable in primary adipocytes of SD rats in normal conditions [79].
It seems that isolation of adipose tissue in mice and its subsequent disturbance
stimulate secretion of inflammatory cytokines, TNF-α, and IL-6 and alter
gene reprogramming in isolated adipocytes [25,26].
CTRP1 in Liver Disease 9
Fig. 2 Effects of CTRP1 on different tissues. (A) Muscle: CTRP1 increases movement of
Glut 4 to plasma membrane of myotubes through phosphorylation of Akt, hence
increases glucose uptake and subsequently reduces blood glucose level. It also
increases fatty acid oxidation in muscle cells through phosphorylation of MAPK.
(B) Liver: CTRP1 causes upregulation of HSL and ACC in liver, but it induces fatty acid
oxidation and inhibits fatty acid synthesis by phosphorylation and inactivation of
ACC. (C) Heart: CTRP1 exerts antiinflammatory effect in myocardial infarction milieu
by abolishing induced expression of TNF-α, IL-6, and IL-1β and phosphorylation of NF-κB
which occurs through SP1 activation. (D) Adrenal cortex: CTRP1 enhances aldosterone
production by upregulating Nurr1 and NGFIB and consequently CYP11B1. (E) Vessels:
CTRP1 exerts anticoagulatory effect by inhibiting aggregation and activation of
platelets.
10 P. Shabani et al.
1. INTRODUCTION
Exosomes and microvesicles, collectively referred to as extracellular
vesicles (EVs), are submicroscopic lipid vesicles released by various types
of cells to extracellular environment [1]. EVs play significant roles in cell-
to-cell communications by carrying cell signaling molecules, such as
DNA, mRNA, microRNA, proteins, and lipids, to the recipient cells
[2,3]. Exosomes have diameters from 30 to 100 nm formed by inward bud-
ding to late endosome. After exosomes are held in multivesicular bodies
(MVB) in the cell, they are released by exocytosis pathway [4,5]. Micro-
vesicles, on the other hand, have a diameter from 100 to 1000 nm and
are formed by outward budding and fission of the plasma membrane [4].
The lipid composition of EVs is similar to that of the cell membrane but
it has an increased level of the aminophospholipids, phosphatidylserine
(PS), and phosphatidylethanolamine, compared to the outer leaflet of the
cell membrane [1]. In addition, the membrane of exosomes contains the
lipid ceramide formed during the production of exosomes [5].
Recently, a number of studies have revealed that EVs play significant
roles in cancer progression and metastasis, and the immune system [6–8].
Applications of EVs to diagnosis and therapeutics have been of great interest
in both academia and industry. However, the detection method of EVs is
still under development because of their submicroscopic sizes and heteroge-
neous cellular origins. In this review, we will briefly discuss the functions of
EVs in the biological system, the isolation, and characterization methods of
EVs, and the recent advances of the peptide probes that sense the curvature
and lipid composition of EVs (Fig. 1).
2. Bark-drawing of emu.
3. Rock-drawing of lizard.
4. Rock-drawing of fish.
PLATE L